

Colorado Consortium for Prescription Drug Abuse Prevention

PDMP Work Group Meeting

January 11, 2024 from 3:30 to 4:30 p.m. via Zoom

Present:

Jason Hoppe, DO and Dmitry Kunin, DORA, Co-chairs

Justin Wipf, DORA

Diane Matt, Colorado Veterinary Medical Association

Nagy Ramzy, Pharmacist, Ret.

Tamara Mattox, Crowe, LLP

Timothy White

CDPHE, Barbara Gabella, Katie Sullivan

Consortium: Jose Esquibel, Gina Olberding, Shayna Micucci, Jessica Eaddy

Absent: See attached list.

Consortium Director, Jose Esquibel, called the meeting to order at 3:35 p.m.

Approval of Minutes:

A motion was made to approve the September 2023 work group meeting minutes. Motion approved.

Legislative Updates Related to the PDMP (Jose Esquibel):

Jose updated work group members on bills currently being introduced. Items pertaining to the PDMP are in the Prevention bill. Once bills are officially introduced, information will be emailed to work group members for possible amendments and other suggestions to be considered during bill hearings. Jose asked members to let him know if they would like to provide testimony or need assistance in contacting bill sponsors. Jose.a.esquibel@cuanschutz.edu

[SB24-047 Prevention of Substance Use Disorders](#) was assigned to the Senate Health and Human Services Committee. The bill sponsors are Senator Priola, Representative Mary Young, and Representative Elisabeth Epps.

Prescription Drug Abuse Monitoring Program (PDMP):

- Exempts veterinarians from some aspects of the PDMP (Sections 1, 6, and 8)
- Requires reporting on gabapentin in addition to prescriptions for controlled substances in the PDMP (Section 2, 4, 5, and 6)
- Allows the Department of Health Care Policy and Finance access to the PMDP for review and analysis of data, consistent with federally required reporting relating to recipients of certain benefits (Section 5)
- Updates current language in the laws relating to the PDMP by using more modern terminology (Sections 4 and 5)
- Allows the medical director of a practice or hospital to appoint designees for querying the PDMP on behalf of a practitioner in the medical practice or hospital setting (Sections 3, 4, and 5)

- Allows for application for a waiver from reporting on gabapentin in the PDMP due to a lack of electronic automation (Section 7)

A copy of the bill summaries is attached to the minutes.

Questions were raised regarding xylazine and federal laws. Katie Sullivan said it is her understanding that xylazine is not yet considered a controlled substance, but is under congressional consideration. Diane Matt mentioned the importance of xylazine for large animal anesthetization and sedation, and the diversion is not due to veterinary sources but rather supplies coming from places like China. Some states have made xylazine a schedule II drug, which makes it unavailable for veterinary use.

Diane provided the following links:

<https://www.bovinevetonline.com/news/education/xylazine-bill-protects-veterinary-access-sedative>

<https://www.avma.org/blog/avma-endorses-federal-legislation-address-illicit-xylazine>

Member Updates (Dmitry Kunin and Justin Wipf):

Task Force requests have been received from the Executive Director for the PDMP annual report. A copy of the requests is attached to the minutes.

Justin Wipf reviewed the requests and tasks listed in the Executive Director's submission:

- Evaluation of changes to the PDMP data being used for practice, evaluation, or research purposes was eliminated.
- DORA will be reviewing ways to promote PDMP utilization; integration hasn't guaranteed that practitioners will consult the PDMP.
- Training to promote PDMP use will be reviewed.
- A number of states require practitioners to report administration or dispensation of controlled substances to the PDMP.

Justin said he would welcome Diane's veterinary perspective regarding PDMP requirements. A brief discussion ensued regarding the differences between veterinary reporting practices and practices related to patients.

Improving Emergency Department PDMP Use (Jason Hoppe):

Jason reviewed a project related to improving ER use of the PDMP. The project results will be published in the Annals of Emergency Medicine. A copy is attached to the minutes. A new project will review mandates and their impact.

Jose commented that the data presented by Jason has an impact on both practice and policy and that some of the information might be integrated into the Consortium's provider education efforts. Jason noted that not much has been done to educate providers on integration and other changes. Justin said some states have been more aggressive in educating providers.

Recognition of Consortium Key Leaders:

Contributors to the Consortium's work over the past decade were recognized during the annual meeting held in October. Jason Hoppe was recognized for his work and leadership over the past 10 years. Dmitry Kunin and Justin Wipf were also thanked for their continued contributions to the work group efforts.

Adjournment/Next Meeting:

The meeting was adjourned at 3 p.m. The next work group meeting will be held on Thursday, March 14, 2024 from 3:30 to 4:30 p.m.

Attachments: Work group roster, Summary of pending legislation, DORA Executive Director letter, Reports